Renhe Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company" or "this Company") and all members of the board of directors guarantee that the content of this information disclosure is true, accurate, and complete, without false records, misleading statements, or major omissions.
On April 22, 2026, the Company held the seventh meeting of the tenth board of directors, where it reviewed and approved the proposal for the share repurchase plan through centralized bidding. The Company decided to use its own funds of RMB 80 million to 150 million to repurchase part of the public shares through centralized bidding, for the purpose of implementing equity incentives or employee stock ownership plans. The repurchase price will not exceed RMB 8.00 per share (inclusive), and the estimated number of shares to be repurchased is between 10 million and 18.75 million shares (accounting for 0.71% to 1.34% of the Company's current total share capital). The specific number of repurchased shares will be based on the actual number of shares repurchased by the end of the repurchase period. The implementation period for this share repurchase is no more than 12 months from the date the board of directors approved the repurchase plan.